Social networks
1,292 26,604Activities
Technologies
Entity types
Location
540-1385 W 8th Ave, Vancouver, BC V6H 3V9, Canada
Vancouver
Canada
Employees
Scale: 201-500
Estimated: 293
Engaged corporates
10Added in Motherbase
2 years, 9 months agoDeveloping novel medicines for patients with difficult-to-treat cancers and other serious diseases.
Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates.
Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary AzymetricTM technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been submitted. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S.
Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.
antibody therapeutics, bispecific antibodies, effector function modulation, ADC, Breast Cancer, Gastric Cancer, protein engineering, Immune redirection, and Biliary Tract Cancer
Developing novel medicines for patients with difficult-to-treat cancers and other serious diseases
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
KPMG Consulting, audit, Accounting | KPMG Consulting, audit, Accounting | Other 13 Feb 2024 | | |
Nasdaq Finance, Financial Services | Nasdaq Finance, Financial Services | Other 15 Jan 2023 | | |
MSD Pharmaceutical, Pharmaceutical Manufacturing | MSD Pharmaceutical, Pharmaceutical Manufacturing | Other 11 May 2021 | | |
Incyte Pharmaceutical, Pharmaceutical Manufacturing | Incyte Pharmaceutical, Pharmaceutical Manufacturing | Other 14 Feb 2022 | | |
Amgen Biotechnology, Biotechnology Research | Amgen Biotechnology, Biotechnology Research | Other 11 Oct 2021 | | |
Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Pfizer Pharmaceutical, Pharmaceutical Manufacturing | Other 18 Jun 2020 | | |
Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Servier Pharmaceuticals Pharmaceutical, Pharmaceutical Manufacturing | Other 12 May 2022 | | |
Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Novo Nordisk Pharmaceutical, Pharmaceutical Manufacturing | Other 14 Nov 2019 | | |
Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Johnson & Johnson Pharmaceutical, Hospitals and Health Care | Capitalistic Not partnership Not event 14 Nov 2017 | | |
Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Merck Group Pharmaceutical, Biotechnology, Pharmaceutical Manufacturing | Not capitalistic Partnership Not event 14 May 2021 | |